![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received for publication August 15, 2007.
Revised November 26, 2007.
Accepted for publication November 26, 2007.
Posttransplant diabetes is an untoward effect often observed under immunosuppressive therapy with cyclosporin A. Besides the development of peripheral insulin resistance and a decrease in insulin gene transcription a beta-cell toxic effect has been described. However, its molecular mechanism remains unknown. In the present study the effect of cyclosporin A and the dual leucine zipper bearing kinase (DLK) on beta-cell survival was investigated. Cyclosporin A decreased the viability of the insulin producing pancreatic islet cell line HIT in a time- and concentration-dependent manner. Upon exposure to the immunosuppressant fragmentation of DNA, the activation of the effector caspase-3 as well as a decrease of full length caspase-3 and BclXL were observed in HIT cells and in primary mature murine islets, respectively. Cyclosporin A and tacrolimus, both potent inhibitors of the calcium/calmodulin-dependent phosphatase calcineurin, stimulated the enzymatic activity of cellular DLK in an in vitro kinase assay. Immunocytochemistry revealed that the overexpression of DLK, but not its kinase-dead mutant, induced apoptosis and enhanced cyclosporin A-induced apoptosis to a higher extent than the drug alone. Moreover, in the presence of DLK the effective concentration for cyclosporin A-caused apoptosis was similar to its known IC50 value for the inhibition of calcineurin activity in beta-cells. These data suggest, that cyclosporin A through inhibition of calcineurin activates DLK, thereby leading to beta-cell apoptosis. This action may thus be a novel mechanism through which cyclosporin A precipitates posttransplant diabetes.
Key words:
Protein Kinases (other), Protein ser/thr Phosphatases, MAP Kinase, Apoptosis, Endocrine cells